|1.||Ishida, Takashi: 5 articles (10/2015 - 03/2010)|
|2.||Ueda, Ryuzo: 5 articles (10/2015 - 03/2010)|
|3.||Akinaga, Shiro: 3 articles (03/2012 - 03/2010)|
|4.||Utsunomiya, Atae: 3 articles (03/2012 - 03/2010)|
|5.||Iida, Shinsuke: 2 articles (10/2015 - 03/2010)|
|6.||Miyamoto, Toshihiro: 2 articles (03/2013 - 03/2012)|
|7.||Tobinai, Kensei: 2 articles (03/2012 - 03/2010)|
|8.||Inagaki, Hiroshi: 2 articles (03/2012 - 03/2010)|
|9.||Uike, Naokuni: 2 articles (03/2012 - 03/2010)|
|10.||Tsukasaki, Kunihiro: 2 articles (03/2012 - 03/2010)|
|1.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
03/01/2010 - "The first aim of the present study was to evaluate whether the antitumor activity of KW-0761 would likely be sufficient for therapeutic clinical application against ATLL. "
03/01/2010 - "KW-0761 should be sufficiently active for therapeutic clinical application for ATLL. "
03/01/2010 - "The degree of KW-0761 ADCC against primary ATLL cells in an autologous setting was mainly determined by the amount of effector natural killer cells present, but not the amount of the target molecule CCR4 on the ATLL cell surface. "
03/01/2010 - "In addition, KW-0761 showed potent antitumor activity mediated by highly enhanced ADCC against primary ATLL cells both in vitro and ex vivo in an autologous setting. "
03/01/2010 - "KW-0761 showed potent antitumor activity against ATLL cell lines both in vitro and in the ATLL mouse model in vivo. "
|2.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
11/01/2011 - "A phase I study of KW-0761 in relapsed ATL and peripheral T-cell lymphoma was started in 2006, and a subsequent phase II study was completed in 2010. "
03/20/2010 - "This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-positive adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL). "
08/10/2010 - "Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma."
03/20/2010 - "Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma."
10/01/2015 - "Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients."
10/01/2015 - "Depletion of CCR4-expressing FoxP3(+) CD4 Tregs by KW-0761 infusion was investigated in solid cancer patients. "
03/10/2012 - "Further investigation of KW-0761 for treatment of ATL and other T-cell neoplasms is warranted."
03/10/2012 - "Because CC chemokine receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL. "
|5.||T-Cell Lymphoma (Lymphoma, T Cell)
|4.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|5.||Immunoglobulin G (IgG)